Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

134.25 -2.63 (-1.92%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

72 73 Next >

(GILD) - Analyzing Gilead Sciences's Short Interest ↗

December 18, 2023

Via Benzinga

Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy. ↗

December 16, 2023

Lilly's weight loss drug appears to be on the way to becoming a megablockbuster.

Via The Motley Fool

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗

December 15, 2023

These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.

Via InvestorPlace

NASDAQ:GILD is probably undervalued for the fundamentals it is displaying. ↗

December 12, 2023

Investors should take notice ofGILEAD SCIENCES INC (NASDAQ:GILD)—it offers a great deal for the fundamentals it presents.

Via Chartmill

A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street ↗

December 12, 2023

There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock.

Via The Motley Fool

Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas

December 11, 2023

From Gilead Sciences, Inc.

Via Business Wire

A Look Into Gilead Sciences Inc's Price Over Earnings ↗

December 07, 2023

Via Benzinga

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers

December 11, 2023

From Gilead Sciences, Inc.

Via Business Wire

Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

December 11, 2023

From Gilead Sciences, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 11, 2023

Via Benzinga

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today ↗

December 06, 2023

Via Benzinga

Looking Into Gilead Sciences's Recent Short Interest ↗

November 22, 2023

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today ↗

November 21, 2023

Via Benzinga

Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions ↗

December 11, 2023

Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion...

Via Benzinga

Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year

December 11, 2023

From Gilead Sciences, Inc.

Via Business Wire

This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks ↗

December 10, 2023

Regulators are already on the case, and their findings will have financial impacts.

Via The Motley Fool

3 biotech powerhouses poised to thrive amid sector rebound

December 08, 2023

If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.

Via MarketBeat

Topics ETFs

Is NASDAQ:GILD suited for dividend investing? ↗

November 20, 2023

Why the dividend investor may take a look at GILEAD SCIENCES INC (NASDAQ:GILD).

Via Chartmill

Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗

November 15, 2023

Via Benzinga

A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene

December 07, 2023

Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗

December 07, 2023

These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.

Via InvestorPlace

3 Biotech Stocks That Could Be Multibaggers in the Making ↗

November 30, 2023

Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.

Via InvestorPlace

Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

November 30, 2023

From Gilead Sciences, Inc.

Via Business Wire

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

November 30, 2023

These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.

Via The Motley Fool

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies ↗

November 29, 2023

Tuesday, the FDA said it received reports of patients developing T-cell malig

Via Benzinga

J&J, Gilead, BMS: A look at undervalued dividend payers

November 29, 2023

J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown

Via MarketBeat

3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later ↗

November 26, 2023

There's no time like the present to buy these stocks.

Via The Motley Fool

Stocks Stall On November 21, 2023, As Systematic Flows Abate ↗

November 21, 2023

Stocks finished the day lower by roughly 20 bps, which is not a big deal, as rates fell somewhat and the dollar rallied

Via Talk Markets

FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug ↗

November 17, 2023

FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative...

Via Benzinga

In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals. ↗

November 17, 2023

GILEAD SCIENCES INC (NASDAQ:GILD): good value for what you're paying.

Via Chartmill

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.